Immunotech Biopharm Ltd (stock code: 06978, traded as IMMUNOTECH-B) has notified the market that its board of directors will convene on 20 March 2026. The meeting’s primary agenda is to consider and approve the consolidated annual results of the Company and its subsidiaries for the financial year ended 31 December 2025, with a view to releasing these figures for public disclosure.

The announcement, dated 10 March 2026, was signed by Chairman and Executive Director Tan Zheng. The current Board comprises:

• Executive Director: Tan Zheng • Non-executive Directors: Yang Fan, Wang Ruihua, Wang Donghu, Yang Xin, Liu Rui, and Cao Ran • Independent Non-executive Directors: Professor Wang Yingdian, Ng Chi Kit, Peng Sujiu, and Zhang Guoguang

No further financial metrics or performance details were provided in the notice. The forthcoming board meeting will determine the Company’s audited results for FY2025, which will be published subsequently in accordance with Hong Kong listing regulations.